Zdorovʹe Rebenka (Feb 2018)

Antihistamines in the treatment of allergic rhinitis in children

  • A.E. Abaturov,
  • E.L. Krivusha,
  • V.L. Babich

DOI
https://doi.org/10.22141/2224-0551.13.1.2018.127068
Journal volume & issue
Vol. 13, no. 1
pp. 68 – 79

Abstract

Read online

The review of the literature provides current information about the clinical efficacy, safety and tolerability of the classic second-generation H1-antihistamine, desloratadine, in the treatment of allergic rhinitis in children. For writing the article, we used such databases, as Scopus, Web of Science, MedLine, PubMed, Google Scholar. A brief description of the pharmacokinetics and pharmacodynamics of desloratadine, which is a potent and selective inverse agonist for H1-receptors, with the longest half-life, does not penetrate the blood-brain barrier and does not have a sedative effect. Attention is focused on the ability of desloratadine not only to effectively inhibit histamine-associated clinical manifestations of allergic rhinitis, but also to inhibit the activity of the inflammatory process by decreasing the activity of transcription nuclear factor kappa B. Scientific studies demonstrate a high efficacy of desloratadine in the relief of clinical manifestations of allergic rhinitis in children and a good safety profile during its use.

Keywords